Comparative Pharmacology
Head-to-head clinical analysis: ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE versus CARVEDILOL PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE versus CARVEDILOL PHOSPHATE.
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE vs CARVEDILOL PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Articaine is an amide local anesthetic that blocks sodium ion channels in nerve cell membranes, preventing depolarization and conduction of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the anesthetic effect by reducing local blood flow and systemic absorption.
Competitive beta-blocker with alpha1-blocking activity; decreases cardiac output, reduces peripheral vascular resistance.
Adults: 1:100,000 epinephrine formulation (4% articaine) administered as a submucosal local infiltration or nerve block; maximum dose 7 mg/kg (0.175 mL/kg) per appointment, not to exceed 500 mg (12.5 mL). 1:200,000 epinephrine formulation may be used; maximum dose same.
6.25 mg orally twice daily, titrated up to a maximum of 25 mg twice daily for heart failure; 12.5 mg orally once daily for hypertension, titrated to 25-50 mg daily.
None Documented
None Documented
Articaine: terminal half-life ~20 minutes (0.33 h) in plasma; clinical context: rapid elimination limits systemic toxicity. Epinephrine: short half-life ~2 minutes; clinical effect terminated by uptake and metabolism.
7-10 hours (terminal elimination half-life); clinical context: supports twice-daily dosing for sustained beta-blockade.
Articaine is primarily metabolized by plasma esterases; its inactive metabolite articainic acid is excreted renally (approximately 90% as metabolites, <2% unchanged). Epinephrine is metabolized by COMT and MAO; metabolites and small amounts unchanged are excreted in urine (~90% renal).
Primarily hepatic metabolism (CYP2D6 and CYP2C9) followed by biliary excretion into feces; ~60% fecal elimination as metabolites, ~16% renal elimination of unchanged drug plus metabolites.
Category A/B
Category C
Alpha/Beta Agonist
Alpha/Beta-Blocker